3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
38
Nivolumab
24
atezolizumab
10
Ipilimumab
7
Carboplatin
6
avelumab
5
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Docetaxel
5
Cyclophosphamide
5
fludarabine
4
cabozantinib
4
Specimen Handling
4
Pemetrexed
4
regorafenib
3
Interleukin-2
3
Gemcitabine
3
130-nm albumin-bound paclitaxel
3
spartalizumab
2
lenvatinib
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Immune Checkpoint Inhibitors
2
Cisplatin
2
Biopsy
2
Albumin-Bound Paclitaxel
2
zanidatamab
1
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
Solutions
×
Thoracic
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled